Phase I/II trial of vorinostat (SAHA) and erlotinib for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations after erlotinib progression

Lung Cancer

Volumn 84, Issue 2, 2014, Pages 161-167

  Reguart, Noemi ^a   Rosell, Rafael ^b,c   Cardenal, Felipe ^d   Cardona, Andres F ^e   Isla, Dolores ^f   Palmero, Ramon ^d   Moran, Teresa ^b   Rolfo, Christian ^g   Pallarès, M Cinta ^h   Insa, Amelia ⁱ   Carcereny, Enric ^b   Majem, Margarita ^h   De Castro, Javier ^j   Queralt, Cristina ^b   Molina, Miguel A ^c   Taron, Miquel ^b,c  

^a HOSPITAL CLÍNIC   (Spain)

^b HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^c HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^d CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^e HOSPITAL UNIVERSITARIO FUNDACIÓN SANTA FE DE BOGOTÁ   (Colombia)

^f HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

^g ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^h HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

ⁱ HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^j HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

more..

Author keywords

EGFR mutations; Erlotinib; Histone deacetylase inhibitors; NSCLC; TKIs resistance; Vorinostat

Indexed keywords

CREATININE; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; VORINOSTAT; ANTINEOPLASTIC AGENT; EGFR PROTEIN, HUMAN; HYDROXAMIC ACID; QUINAZOLINE DERIVATIVE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHEILITIS; CLINICAL ARTICLE; CONSTIPATION; DEHYDRATION; DIARRHEA; DRUG DOSE ESCALATION; DRY SKIN; DYSGEUSIA; DYSPEPSIA; EPIGASTRIC PAIN; ERYTHEMA; FATIGUE; FEMALE; FEVER; HUMAN; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; HYPERKALEMIA; LUNG NON SMALL CELL CANCER; LYMPHOCYTOPENIA; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MUCOSA INFLAMMATION; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; PARONYCHIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; RASH; RECOMMENDED DRUG DOSE; SIDE EFFECT; SOMNOLENCE; THIRST; VOMITING; XEROSTOMIA; ADENOCARCINOMA; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; DRUG POTENTIATION; DRUG RESISTANCE; GENETICS; KAPLAN MEIER METHOD; LUNG NEOPLASMS; MISSENSE MUTATION; MORTALITY; TREATMENT OUTCOME;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FEMALE; HUMANS; HYDROXAMIC ACIDS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION, MISSENSE; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TREATMENT OUTCOME;

EID: 84899471596     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2014.02.011     Document Type: Article

References (41)

1. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004, 350:2129-2139.
2. Paez J.G., Janne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304:1497-1500.
3. Shigematsu H., Lin L., Takahashi T., Nomura M., Suzuki M., Wistuba I.I., et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005, 97:339-346.
4. Rosell R., Moran T., Queralt C., Porta R., Cardenal F., Camps C., et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009, 361:958-967.
5. Mok T.S., Wu Y.L., Thongprasert S., Yang C.H., Chu D.T., Saijo N., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009, 361:947-957.
6. Maemondo M., Inoue A., Kobayashi K., Sugawara S., Oizumi S., Isobe H., et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010, 362:2380-2388.
7. Mitsudomi T., Morita S., Yatabe Y., Negoro S., Okamoto I., Tsurutani J., et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010, 11:121-128.
8. Zhou C., Wu Y., Chen G., Feng J., Liu X., Wang C., et al. Updated efficacy and quality-of-life (QoL) analyses in OPTIMAL, a phase III, randomized, open-label study of first-line erlotinib versus gemcitabine/carboplatin in patients with EGFR-activating mutation-positive (EGFR Act Mut+) advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2011, 29.
9. Rosell R., Gervais R., Vergnenegre A., Massuti B., Felip E., Cardenal F., et al. Erlotinib versus chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations: Interim results of the European Erlotinib Versus Chemotherapy (EURTAC) phase III randomized trial. J Clin Oncol 2011, 29.
10. Sequist L.V., Yang J.C., Yamamoto N., O'Byrne K., Hirsh V., Mok T., et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013.
11. Jackman D., Pao W., Riely G.J., Engelman J.A., Kris M.G., Janne P.A., et al. Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. J Clin Oncol 2010, 28:357-360.
12. Kobayashi S., Boggon T.J., Dayaram T., Janne P.A., Kocher O., Meyerson M., et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005, 352:786-792.
13. Pao W., Miller V.A., Politi K.A., Riely G.J., Somwar R., Zakowski M.F., et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005, 2:e73.
14. Oxnard G.R., Morris M.J., Hodi F.S., Baker L.H., Kris M.G., Venook A.P., et al. When progressive disease does not mean treatment failure: reconsidering the criteria for progression. J Natl Cancer Inst 2012.
15. Engelman J.A., Zejnullahu K., Mitsudomi T., Song Y., Hyland C., Park J.O., et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007, 316:1039-1043.
16. Sequist L.V., Waltman B.A., Dias-Santagata D., Digumarthy S., Turke A.B., Fidias P., et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011, 3:75ra26.
17. Janjigian Y.Y., Azzoli C.G., Krug L.M., Pereira L.K., Rizvi N.A., Pietanza M.C., et al. Phase I/II trial of cetuximab and erlotinib in patients with lung adenocarcinoma and acquired resistance to erlotinib. Clin Cancer Res 2011, 17:2521-2527.
18. Janjigian Y.Y., Groen H.J., Horn L., Smit E.F., Fu Y., Wang F., et al. Activity and tolerability of afatinib (BIBW 2992) and cetuximab in NSCLC patients with acquired resistance to erlotinib or gefitinib. J Clin Oncol 2011, 29.
19. Zhou W., Ercan D., Chen L., Yun C.H., Li D., Capelletti M., et al. Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature 2009, 462:1070-1074.
20. Kwak E.L., Sordella R., Bell D.W., Godin-Heymann N., Okimoto R.A., Brannigan B.W., et al. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci U S A 2005, 102:7665-7670.
21. Rekhtman N., Paik P.K., Arcila M.E., Tafe L.J., Oxnard G.R., Moreira A.L., et al. Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations. Clin Cancer Res 2012, 18:1167-1176.
22. Bali P., Pranpat M., Bradner J., Balasis M., Fiskus W., Guo F., et al. Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. J Biol Chem 2005, 280:26729-26734.
23. Rao R., Fiskus W., Yang Y., Lee P., Joshi R., Fernandez P., et al. HDAC6 inhibition enhances 17-AAG-mediated abrogation of hsp90 chaperone function in human leukemia cells. Blood 2008, 112:1886-1893.
24. Shimamura T., Lowell A.M., Engelman J.A., Shapiro G.I. Epidermal growth factor receptors harboring kinase domain mutations associate with the heat shock protein 90 chaperone and are destabilized following exposure to geldanamycins. Cancer Res 2005, 65:6401-6408.
25. Yang S., Qu S., Perez-Tores M., Sawai A., Rosen N., Solit D.B., et al. Association with HSP90 inhibits Cbl-mediated down-regulation of mutant epidermal growth factor receptors. Cancer Res 2006, 66:6990-6997.
26. Sequist L.V., Gettinger S., Senzer N.N., Martins R.G., Janne P.A., Lilenbaum R., et al. Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer. J Clin Oncol 2010, 28:4953-4960.
27. Edwards A., Li J., Atadja P., Bhalla K., Haura E.B. Effect of the histone deacetylase inhibitor LBH589 against epidermal growth factor receptor-dependent human lung cancer cells. Mol Cancer Ther 2007, 6:2515-2524.
28. Kakihana M., Ohira T., Chan D., Webster R.B., Kato H., Drabkin H.A., et al. Induction of E-cadherin in lung cancer and interaction with growth suppression by histone deacetylase inhibition. J Thorac Oncol 2009, 4:1455-1465.
29. Witta S.E., Gemmill R.M., Hirsch F.R., Coldren C.D., Hedman K., Ravdel L., et al. Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines. Cancer Res 2006, 66:944-950.
30. Butler L.M., Agus D.B., Scher H.I., Higgins B., Rose A., Cordon-Cardo C., et al. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res 2000, 60:5165-5170.
31. Mann B.S., Johnson J.R., Cohen M.H., Justice R., Pazdur R. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist 2007, 12:1247-1252.
32. Ramalingam S.S., Parise R.A., Ramanathan R.K., Lagattuta T.F., Musguire L.A., Stoller R.G., et al. Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies. Clin Cancer Res 2007, 13:3605-3610.
33. Fakih M.G., Pendyala L., Fetterly G., Toth K., Zwiebel J.A., Espinoza-Delgado I., et al. A phase I, pharmacokinetic and pharmacodynamic study on vorinostat in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with refractory colorectal cancer. Clin Cancer Res 2009, 15:3189-3195.
34. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92:205-216.
35. Fleming T.R. One-sample multiple testing procedure for phase II clinical trials. Biometrics 1982, 38:143-151.
36. Jotte R.M., Witta S.E., Spira A. Molecular analysis identifies a subset of non-small cell lung cancer patients with differential sensitivity to histone deacetylase inhibitor (HDACI)/epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) treatment. J Thorac Oncol 2010, 5:S559-S560.
37. Kuang Y., Rogers A., Yeap B.Y., Wang L., Makrigiorgos M., Vetrand K., et al. Noninvasive detection of EGFR T790M in gefitinib or erlotinib resistant non-small cell lung cancer. Clin Cancer Res 2009, 15:2630-2636.
38. Rosell R., Molina M.A., Costa C., Simonetti S., Gimenez-Capitan A., Bertran-Alamillo J., et al. Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations. Clin Cancer Res 2011, 17:1160-1168.
39. Oxnard G.R., Arcila M.E., Sima C.S., Riely G.J., Chmielecki J., Kris M.G., et al. Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation. Clin Cancer Res 2011, 17:1616-1622.
40. Chmielecki J, Foo J, Somwar R, Regales L, Vivanco I, Shen R. EGFR T7990M decreases growth potential of lung tumor cells with drug-sensitive EGFR mutant alleles in the presence of drug selection. AACR 100th Annual Meeting 2009; Abstract 4217.
41. Kelly W.K., O'Connor O.A., Krug L.M., Chiao J.H., Heaney M., Curley T., et al. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 2005, 23:3923-3931.